Corporate Tech Investors

Alnylam Pharmaceuticals

Alnylam Pharmaceuticals is a corporate venture capital group that makes equity investment in firms that align with the company's business objectives.

Venture Investor Overview

Contact Information

Background Information

Overview

Alnylam (NASDAQ: ALNY) is developing an entirely new class of innovative medicines based on a breakthrough discovery in biology known as RNA interference, or RNAi. With RNAi technology, we have the opportunity to treat disease and impact the lives of patients in a fundamentally new way by silencing disease-causing genes upstream of today's medicines.

Profile

Social Media

Company News

Facebook

YouTube

Last Transaction

3/4/2009

Transaction History

Our records indicate that Alnylam Pharmaceuticals invested in the VC transactions listed below. Dollar amounts are for the entire raise, which may include other investors.

Investor Contacts

Title

Name

Email & Social

Chief Executive Officer

John Maraganore

        

Funds

No fund closings have been recorded for this company.

Portfolio Companies

Alnylam Pharmaceuticals has invested in only one tech company, according to our database records. If we are missing a portfolio company, please let us know.

Browse more corporate investors:

Almirall | Alopexx

Share this article

About Our Corporate Tech Investor Database

The strategic investor data above is provided by VentureDeal.com, a leading provider of corporate tech investing transaction data.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary